Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
December 7, 2023 | Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,000 | -- | 80,000 | |
June 15, 2020 | Controller | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 80,000 | -- | 69,557 | |
June 15, 2020 | Controller | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,000 | -- | 149,557 | |
May 15, 2018 | Controller | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,000 | -- | 99,557 | |
May 6, 2013 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,000 | -- | 385,000 | |
May 6, 2013 | SVP Investor Relations | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,000 | -- | 300,000 | |
February 19, 2010 | Chief Executive Offier | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 85,000 | $2.94 | 698,334 | |
June 15, 2012 | CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 87,000 | $2.15 | 965,000 | |
March 17, 2023 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 90,000 | -- | 320,000 | |
June 13, 2022 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 90,000 | -- | 303,068 | |
February 22, 2005 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 98,684 | -- | 620,095 | |
May 15, 2018 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 124,643 | |
February 11, 2014 | CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 358,885 | |
July 6, 2010 | Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | $3.39 | 100,000 | |
December 8, 2008 | Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | $3.00 | 100,000 | |
February 22, 2005 | Director, Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 1,820,000 | |
February 22, 2005 | VP, General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 300,000 | |
June 9, 2004 | Executive VP & Chief Op. Off. | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 1,720,000 | |
May 13, 2024 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 112,500 | -- | 126,666 | |
September 6, 2016 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 125,000 | -- | 923,885 | |
June 15, 2020 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 135,000 | -- | 1,346,071 | |
March 17, 2015 | Director, CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 140,000 | -- | 583,885 | |
June 20, 2014 | Director, CEO | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 140,556 | -- | 443,885 | |
February 2, 2016 | Director, CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 150,000 | -- | 798,885 | |
June 20, 2014 | CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 150,000 | -- | 508,885 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.